PepPool: SARS-CoV-2 (NMO), human

PepPool: SARS-CoV-2 (NMO), human


Publications: 4
Validated for our assays.


Peptide pool with 101 peptides, 25 ug of each peptide. Supplied in one vial (lyophilized).

In stock

Delivery 4-9 business days

Shipping $0

Product specifications

Intended use

This peptide pool is intended for studying immune responses against SARS-CoV-2 (N, M, and O proteins) using immunoassays such as ELISpot and FluoroSpot. It induces cytokine secretion from antigen-specific human T cells. For research use only. Not for use in diagnostic procedures.

Serum/Plasma samples

The SARS-CoV-2 (NMO) defined peptide pool induces secretion of e.g., IFN-γ, IL-2, and granzyme B from human T cells. It contains 101 peptides from the human SARS-CoV-2 virus. The peptides are derived from the nucleoprotein (N), membrane protein (M) and open reading frame (ORF) proteins (O) ORF1, nsp3, ORF-3a, ORF-7a, and ORF8. The mean purity of the synthetic peptides is 87%.

The peptide pool has been validated using human PBMC from COVID-19 convalescent individuals.

Published HLA types covered by the SARS-CoV-2 NMO defined peptide pool are listed in the datasheet.


Product details

ProductPepPool: SARS-CoV-2 (NMO), human
ApplicationT cell stimulation, ELISpot, FluoroSpot, Flow cytometry
Supplied in



Peptide pool with 101 peptides, 25 ug of each peptide. Supplied in one vial (lyophilized).

Shipping and Storage


Shipped at ambient temperature.


Store at -20 °C or below upon receipt. 

Human PBMC (250,000 cells/well) from one COVID-19 vaccinated individual (mRNA vaccine with spike sequence), one COVID-19 convalescent individual, and from one individual collected before the SARS-CoV-2 pandemic were incubated overnight in the absence or presence of the SARS-CoV-2 NMO defined peptide pool and anti-CD28 mAb. The number of cells secreting IFN-γ was analyzed by ELISpot using Mabtech IRIS.

Highlighted research, Published May 17, 2022

Third vaccine dose important for T cell response against Omicron
Three doses mRNA vaccine had better T cell responses than recipients of two doses. Mabtech IRIS and FluoroSpot Flex: Human IFN-γ/TNF-α/IL-2/Granzyme B were used to assess T cell immunity in mRNA vaccine recipients.
Loading publications...
1 / 1